Acurx Pharmaceuticals, Inc. (ACXP)
ACXPNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.06
+0.0302 (+2.93%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $1.07 +3.88%
- Market cap
- $5.95m
- P/E
- –
- EPS, last 4 quarters
- $-2.69
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9457 to $7.54
- Average volume
- –
- Previous close
- $1.03
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $17.00, +1503.5% from here
Earnings
next estimate $-0.4500Next report
Sep 2025
+23.6%
Dec 2025
+69.3%
Mar 2026
-5.1%
Jun 2026
-26.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.03m | -$1.62m | -$1.72m | -$2.31m |
| Net income | -$1.99m | -$1.58m | -$1.68m | -$2.25m |
News
8 latest- Acurx Pharmaceuticals, Inc. Amends Bylaws to Reduce Stockholder Quorum to 33⅓%Fintel · Nov 2, 2026
- Acurx Gets FDA Conditional Acceptance, U.S. Patents Trademark Allowance For Ibezapolstat Brand Name RTTNews · Aug 18, 2026
- Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's WhyZacks · Jun 8, 2026
- Acurx (ACXP) Q1 2026 Earnings TranscriptThe Motley Fool · May 12, 2026
- Acurx Pharma Prices $7.1 Mln Offering Of Shares And Short-Term Warrants; Stock Down RTTNews · Apr 16, 2026
- Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?Zacks · Apr 2, 2026
- Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?Zacks · Mar 19, 2026
- Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?Zacks · Mar 17, 2026
The company
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for serious and life threatening bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- acurxpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.